AU2007333147B2 - Oligonucleotides containing high concentrations of guanine monomers - Google Patents

Oligonucleotides containing high concentrations of guanine monomers Download PDF

Info

Publication number
AU2007333147B2
AU2007333147B2 AU2007333147A AU2007333147A AU2007333147B2 AU 2007333147 B2 AU2007333147 B2 AU 2007333147B2 AU 2007333147 A AU2007333147 A AU 2007333147A AU 2007333147 A AU2007333147 A AU 2007333147A AU 2007333147 B2 AU2007333147 B2 AU 2007333147B2
Authority
AU
Australia
Prior art keywords
oligonucleotide
solvent
seq
coupling
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007333147A
Other languages
English (en)
Other versions
AU2007333147A1 (en
Inventor
Brian Stephen Sproat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuros US LLC
Original Assignee
Kuros US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuros US LLC filed Critical Kuros US LLC
Publication of AU2007333147A1 publication Critical patent/AU2007333147A1/en
Assigned to CYTOS BIOTECHNOLOGY AG reassignment CYTOS BIOTECHNOLOGY AG Request for Assignment Assignors: INTEGRATED DNA TECHNOLOGIES, INC.
Priority to AU2013204442A priority Critical patent/AU2013204442A1/en
Application granted granted Critical
Publication of AU2007333147B2 publication Critical patent/AU2007333147B2/en
Assigned to KUROS BIOSCIENCES AG reassignment KUROS BIOSCIENCES AG Request to Amend Deed and Register Assignors: CYTOS BIOTECHNOLOGY AG
Assigned to KUROS US LLC reassignment KUROS US LLC Request for Assignment Assignors: KUROS BIOSCIENCES AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007333147A 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers Active AU2007333147B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204442A AU2013204442A1 (en) 2006-12-12 2013-04-12 Oligonucleotides Containing High Concentrations of Guanine Monomers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86958806P 2006-12-12 2006-12-12
US60/869,588 2006-12-12
PCT/US2007/087183 WO2008073960A2 (en) 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013204442A Division AU2013204442A1 (en) 2006-12-12 2013-04-12 Oligonucleotides Containing High Concentrations of Guanine Monomers

Publications (2)

Publication Number Publication Date
AU2007333147A1 AU2007333147A1 (en) 2008-06-19
AU2007333147B2 true AU2007333147B2 (en) 2013-12-19

Family

ID=39456527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007333147A Active AU2007333147B2 (en) 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers

Country Status (7)

Country Link
US (3) US8586728B2 (enExample)
EP (1) EP2125854B1 (enExample)
JP (1) JP5389662B2 (enExample)
CN (1) CN101611048B (enExample)
AU (1) AU2007333147B2 (enExample)
CA (1) CA2671873C (enExample)
WO (1) WO2008073960A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008063490B4 (de) * 2008-12-17 2023-06-15 Merck Patent Gmbh Organische Elektrolumineszenzvorrichtung und Verfahren zum Einstellen des Farbortes einer weiß emittierenden Elektrolumineszenzvorrichtung
WO2012059510A1 (en) 2010-11-02 2012-05-10 Girindus America, Inc. Back pressure control during solid-phase synthesis on polymeric supports
US10040048B1 (en) 2014-09-25 2018-08-07 Synthego Corporation Automated modular system and method for production of biopolymers
HUE053145T2 (hu) 2014-12-31 2021-06-28 Checkmate Pharmaceuticals Inc Kombinált tumor immunterápia
WO2017005818A1 (en) * 2015-07-08 2017-01-12 Kuros Biosciences Ag Guanine-rich oligonucleotides
JPWO2017111137A1 (ja) 2015-12-22 2018-10-18 味の素株式会社 オリゴヌクレオチドの製造方法
US20190046638A1 (en) 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
EP3681637A4 (en) 2017-09-11 2021-06-02 Synthego Corporation SYSTEM AND PROCEDURE FOR BIOPOLYMER SYNTHESIS
WO2019080704A1 (zh) * 2017-10-25 2019-05-02 深圳华大生命科学研究院 用于核酸合成的微流控芯片
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
US12049620B2 (en) * 2018-09-11 2024-07-30 Amgen Inc. Purification methods for guanine-rich oligonucleotides
US12655470B2 (en) 2018-10-30 2026-06-16 Toray Industries, Inc. Inhibitor of non-specific binding of nucleic acid, hybridization reagent and nucleic acid hybridization method
CN112969527A (zh) * 2018-11-08 2021-06-15 深圳华大生命科学研究院 一种微流控芯片及其制备方法和dna合成方法
US12202848B2 (en) * 2019-10-18 2025-01-21 Fujifilm Wako Pure Chemical Corporation Phosphoramidite activator
US20230322842A1 (en) * 2020-04-14 2023-10-12 Sumitomo Chemical Company, Limited Composition containing nucleic acid oligomer
CN114425443B (zh) * 2020-10-29 2025-10-31 江苏金斯瑞生物科技有限公司 一种寡核苷酸合成催化剂
GB202114688D0 (en) 2021-10-14 2021-12-01 Exactmer Ltd Solution phase polymer synthesis
GB202414228D0 (en) 2024-09-27 2024-11-13 Exactmer Ltd Solvent recycling in a liquid-phase process for preparing a defined monomoer sequence polymer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
EP1719778A1 (en) * 2004-02-25 2006-11-08 Japan Science and Technology Agency 3'-terminal nucleoside unit containing phosphoramidite

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004749A1 (en) 1983-06-01 1984-12-06 Beckman Instruments Inc Novel preparation of nucleoside phosphoramidite intermediates
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU7350798A (en) 1997-04-29 1998-11-24 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
US6541438B1 (en) 1998-05-01 2003-04-01 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified cellulase
WO2000023955A1 (en) 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
JP2003520568A (ja) 1999-02-02 2003-07-08 バイオカシェ ファーマシューティカルズ， インコーポレイテッド 高度な抗原提示プラットフォーム
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
IL148844A0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
ATE454901T1 (de) 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
WO2001038358A2 (en) 1999-11-24 2001-05-31 Chiron Corporation Hbv/hcv virus-like particle
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1261366A4 (en) 2000-02-24 2003-06-18 Univ Leland Stanford Junior ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS
AU2002248185A1 (en) 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
US7524950B2 (en) * 2001-10-31 2009-04-28 Agilent Technologies, Inc. Uses of cationic salts for polynucleotide synthesis
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
US20060210588A1 (en) 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2004255470B2 (en) 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
WO2006029023A2 (en) * 2004-09-02 2006-03-16 Isis Pharmaceuticals, Inc. Polymeric beads for oligonucleotide synthesis
NZ554387A (en) 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
EP1719778A1 (en) * 2004-02-25 2006-11-08 Japan Science and Technology Agency 3'-terminal nucleoside unit containing phosphoramidite

Also Published As

Publication number Publication date
US9914746B2 (en) 2018-03-13
EP2125854B1 (en) 2016-10-26
US20140200338A1 (en) 2014-07-17
WO2008073960A3 (en) 2008-08-07
CA2671873A1 (en) 2008-06-19
US8586728B2 (en) 2013-11-19
EP2125854A2 (en) 2009-12-02
CN101611048A (zh) 2009-12-23
CN101611048B (zh) 2012-11-07
WO2008073960A2 (en) 2008-06-19
US20080139797A1 (en) 2008-06-12
AU2007333147A1 (en) 2008-06-19
CA2671873C (en) 2018-10-09
JP2010512169A (ja) 2010-04-22
US20160145293A1 (en) 2016-05-26
JP5389662B2 (ja) 2014-01-15

Similar Documents

Publication Publication Date Title
CA2671873C (en) Oligonucleotides containing high concentrations of guanine monomers
Bonora et al. Large scale, liquid phase synthesis of oligonucleotides by the phosphoramidite approach
JP7377228B2 (ja) グアニンリッチオリゴヌクレオチド
EP2332954A2 (en) Process for the preparation of phosphorothionate oligonucleotides
KR102190852B1 (ko) 변형된 커플링 프로토콜을 이용하는 올리고머 화합물의 제조 방법
JP2010248084A (ja) 新規洗浄溶媒を用いるオリゴヌクレオチド合成法
KR20160150051A (ko) Rna 올리고뉴클레오티드 절단 방법
CN102076703B (zh) 用于制造寡核苷酸的方法
EP4294818A1 (en) Process for the de-tritylation of oligonucleotides
EP3650455A1 (en) Solid phase nucleic acid synthesis method and liquid composition for solid phase nucleic acid synthesis
CA2494150A1 (en) Process for separating and deprotecting oligonucleotides
AU2013204442A1 (en) Oligonucleotides Containing High Concentrations of Guanine Monomers
KR20200035267A (ko) 이메텔스타트를 제조하기 위한 향상된 공정
JP2000342265A (ja) オリゴヌクレオチド類の精製方法
KR20260049191A (ko) 올리고뉴클레오티드를 제조하는 방법
WO2023067038A1 (en) Process for oligonucleotide purification
ES2741025T3 (es) Oligonucleótidos ricos en guanina
CN119855824A (zh) 核酸的制造方法、杂质的去除方法以及杂质少的核酸

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYTOS BIOTECHNOLOGY AG

Free format text: FORMER APPLICANT(S): INTEGRATED DNA TECHNOLOGIES, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: KUROS BIOSCIENCES AG

Free format text: FORMER NAME(S): CYTOS BIOTECHNOLOGY AG

PC Assignment registered

Owner name: KUROS US LLC

Free format text: FORMER OWNER(S): KUROS BIOSCIENCES AG